Entrinsic Health Solutions Announces Positive Top Line Clinical Trial Results in Retrospective Study of enterade®
- The retrospective study assesses the effects of an amino acid-based beverage on symptoms of acute gastrointestinal toxicity and side effects of radiotherapy and chemotherapy in cancer patients.
- Detailed data to be presented at the April 2017 SWOG Meeting
- The amino acid-based medical food beverage is also being evaluated in Multiple Myeloma and Non-Hodgkin lymphoma patients with a Phase II clinical study with analysis expected in the third quarter of 2017
NORWOOD, Mass., April 27, 2017 – (PR Newswire) Entrinsic Health Solutions, Inc., an innovative health sciences company dedicated to the development and commercialization of amino acid based medical foods to address critical digestive health, nutrition and hydration related health issues, today announced that it has completed enrollment for its clinical trial for enterade®, “Pragmatic test of amino-acid mixture/enterade® for Gastrointestinal Toxicity in Cancer Therapy.” The study found that 78% of patients who took the product for 7 days or more reported a significant improvement in their side effects from cancer treatment. The Company expects to present detailed data from this trial in future medical conferences beginning with SWOG in April 2017.
Entrinsic Health Solutions launched its pragmatic study with enterade in February 2016. The pragmatic study enrolled a hundred and eighteen patients suffering from acute gastrointestinal toxicity and side effects of radiotherapy and chemotherapy and was designed with a series of endpoints to assess improvement with regards to toxicity symptoms. Patients received treatment with the amino acid-based beverage for an average of 7 days.
“We are very pleased to have completed patient enrollment and accomplished this clinical milestone for Entrinsic. These patients suffer from serious GI toxicity as a result of their cancer therapy and the completion of this trial helps us move closer to our goal of potentially bringing a much needed medical food to people experiencing these serious side effects of cancer therapy,” stated Stephen J. Gatto, Chairman & Chief Executive Office of Entrinsic Health Solutions. “The data from this trial will be an excellent complement to our ongoing trial at the Dana Farber Cancer Institute. We are looking forward to presenting the detailed data later this month and we are very grateful to the patients, their families, and the healthcare providers who participated in this study.”
About Gastrointestinal Toxicity in Cancer Therapy
Gastrointestinal symptoms are a common problem among patients with cancer. Many of these symptoms are iatrogenic, resulting from the surgery, radiation, and/or chemotherapy but can also be caused by the cancer itself. Majority of cancer patients undergo chemotherapy or radiation particularly for patients with various gastrointestinal, bowel, gynecologic, and thoracic malignancies and these patients experience some of the most severe symptoms. Gastrointestinal toxicity can not only reduce quality of life, but it can also lead to premature discontinuation of therapy, purposely missed treatment cycles, and dose reductions all of which could have significant consequences for patients with cancer.
enterade®, is a proprietary, glucose free, medical food/beverage that provides select amino acids and electrolytes (potassium and sodium) – the nutrients needed to rebuild and protect the GI tract and deliver total body hydration to address the side effects for patients undergoing cancer treatments. For more information, please visit us at www.enterade.com and connect with the brand on Facebook, Instagram, and Twitter.
About Entrinsic Health Solutions
Entrinsic Health Solutions, Inc., is an innovative health sciences company dedicated to the development and commercialization of amino acid based medical foods to address critical digestive health, nutrition and hydration related health issues. The Company’s proprietary Amino Acid Coupled Transport (A₂CT) Technology platform leverages gold-standard science and game-changing amino acid technology to address critical digestive- and hydration-related health issues. A2CT technology uses select amino acids to facilitate active transport of electrolytes throughout the body, which delivers rapid hydration, decreased gut permeability and improved nutrient absorption, supporting long-term digestive health. For more information, please visit us at www.entrinsichealth.com.